Barcelona Liver Bioservices (BLB) is pleased to announce a non-exclusive partnership with the global healthcare company Novo Nordisk aimed at characterizing the effects of novel chemical entities developed by Novo Nordisk for the treatment of chronic liver disease.
Barcelona Liver Bioservices in collaboration with Gilead Sciences, is excited to announce the results of an original study that showcases the potential of targeting the LPA pathway in the treatment of advanced chronic liver disease.
Barcelona Liver Bioservices is excited to announce its active participation in the 2nd edition of the International Workshop on Liver and Gut Fibrosis, held in Valencia on 26 & 27 October 2023.
We proudly became active participants in the Industrial Doctorate Program, an initiative championed by the Government of Catalonia.
The Program is designed to foster the competitiveness and international prominence of Catalonia’s industrial sector.
Barcelona Liver Bioservices (BLB), CRO especially focused on the field of Hepatology, announced today the presentation of an original communication at The EASL Congress held in Vienna and organized by the European Association for the Study of Liver Diseases (EASL).
Barcelona Liver Bioservices (BLB) announced today the presentation of an original communication at the annual meeting of the American Association for the Study of the Liver (AASLD), held as The Liver Meeting Digitial Experience.
Barcelona Liver Bioservices (BLB), CRO specialized in liver diseases, announced today the publication of the manuscript entitled “The pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease” in the peer-reviewed scientific journal Journal of Hepatology.
Barcelona Liver Bioservices, CRO specialized in the design and development of pre-clinical studies in the field of liver diseases, announced today a non-exclusive collaboration with Surrozen, a biotech company developing tissue-specific antibodies that have the potential to regenerate tissue in situations of serious diseases.
Barcelona Liver Bioservices, CRO specialized in the design and development of pre-clinical studies in the field of liver diseases, announced today a non-exclusive collaboration with GAT Therapeutics, an early stage biopharma targeting fibrosis and age-related diseases.
Barcelona Liver Bioservices (BLB) announced today the presentation of two communications at the annual meeting of the American Association for the Study of the Liver (AASLD), held in Boston, Massachusetts.
Barcelona Liver Bioservices announced today the publication of the manuscript entitled “A nutraceutical rich in docosahexaenoic acid improves portal hypertension in a preclinical model of advanced chronic liver disease” in the peer-reviewed journal Nutrients.
Barcelona Liver Bioservices (BLB), CRO specialized in liver diseases, announced today the publication of the manuscript entitled “New Rat Model of Advanced NASH Mimicking Pathophysiological Features and Transcriptomic Signature of The Human Disease” in the peer-reviewed journal Cells.
The study characterizes the effects, and underlying mechanisms, of the pan-caspase inhibitor emricasan on portal hypertension, fibrosis and liver cells phenotype in pre-clinical models of advanced cirrhosis.
Barcelona Liver Bioservices (BLB) announced today the presentation of two posters at the annual meeting of the European Association for the Study of the Liver (EASL), held in Vienna.
Barcelona Liver Bioservices (BLB), CRO especially focused on the field of Hepatology, announced today its participation in the upcoming International Liver Congress (ILC) 2019 – the annual meeting of the European Association for the Study of the Liver (EASL) that will take place in Vienna in April 10-14th 2019.
Barcelona Liver Bioservices (BLB) announced today the presentation of a poster describing the mechanisms of action of emricasan in liver cirrhosis at the 69th annual meeting of the American Association for the Study of the Liver (AASLD), held in San Fransico, CA.
Barcelona Liver Bioservices, CRO specialized in the design and development of pre-clinical studies in hepatology, announced today a non-exclusive collaboration with Inventiva, a clinical stage biopharmaceutical company with expertise in fibrosis, oncology and orphan diseases.
The study describes the benefits of using the ExoLiver® platform to simulate the human liver sinusoid on a chip.
Barcelona Liver Bioservices (BLB) announced today the presentation of a poster introducing the BLB’s proprietary experimental model of nonalcoholic steatohepatitis (NASH) at the 42nd annual meeting of the Spanish Association for the Study of the Liver (AEEH), held in Madrid, Spain.
Barcelona Liver Bioservices (BLB) announced today a non-exclusive partnership with the biopharmaceutical company Gilead Sciences to characterize the effects of novel chemical entities developed by Gilead for the treatment of liver diseases, including nonalcoholic steatohepatitis (NASH).